Supported by

Kyowa Kirin strives to create and deliver novel medicines with life-changing value. As a Japan-based Global Specialty Pharmaceutical Company with a heritage of 70+ -years, we apply cutting-edge science including an expertise in antibody research and engineering, to address the needs of patients and society across multiple therapeutic areas including Nephrology, Oncology, Immunology/Allergy and Neurology. Across our four regions – Japan, Asia Pacific, North America and EMEA/International – we focus on our purpose, to make people smile, and are united by our shared values of commitment to life, teamwork/Wa, innovation, and integrity. You can learn more about the business of Kyowa Kirin at: www.kyowakirin.com

Helsinn is a global biopharma company focused on addressing unmet needs in cancer. It has a commercial portfolio of cancer therapeutic and supportive care products underpinning the business as it progresses the research and development with a pipeline of highly innovative oncology assets, building its fully integrated targeted therapies (Helsinn’s FITT strategy). Helsinn is guided by core values of respect, integrity and quality and the Group plays an active role in promoting social transformation in favor of people and the environment.

Mallinckrodt is a global business that develops, manufactures, markets and distributes specialty pharmaceutical products and therapies. Our Specialty Brands segment includes branded medicines and the Specialty Generics segment includes specialty generic drugs, active pharmaceutical ingredients and external manufacturing.

Therakos is a specialty brand of Mallinckrodt that focuses on the delivery of ECP Immunomodulation. The THERAKOSTM CELLEX™ Photopheresis System is the world’s only fully integrated and validated ECP system and is used by over 300 treatment centres in over 30 countries worldwide.

Beyond the THERAKOS™ CELLEX™ Photopheresis System, we offer a comprehensive range of support services to help enable healthcare professionals (HCPs) to deliver optimised ECP immunomodulation to patients.  Therakos have been crafting ECP solutions (products, services and education) since 1987. therakos.eu

At Takeda Oncology, we aspire to cure cancer, with inspiration from patients and innovation from everywhere. We are structured within Takeda to ensure a tight connection from research to development to commercialization and meet the needs of the cancer community, optimizing our ability to bring potentially transformative medicines to market. With demonstrated leadership in the treatment of hematologic cancers and solid tumors, we propel cutting-edge science around the power of innate immunity to enhance and broaden the impact of immunotherapy.

We complement our deep in-house expertise with symbiotic partnerships to unlock promising science wherever it emerges.

For more information.

The single focus of Fresenius Kabi TCT EMEA is to enable our Transfusion Medicine and Cell Therapies (TCT) customers to achieve their mission in the 100+ countries of the region. We are global leaders in apheresis technology for both blood component collection and extracorporeal therapies, bringing new innovations focusing on donor and patient comfort. Besides our broad portfolio, our strength has always been our people. Our expert team is dedicated to forming deep partnerships with our customers, listening to their needs and responding with innovative thinking, collaboration and a shared commitment to the donors and patients we both serve.

Amicus Blue is a time-tested therapeutic apheresis technology offering online ECP with CE mark in Europe since 2019 for the indication of CTCL. Amicus Blue is the only multi-procedural platform available in EMEA that offers a true online ECP procedure to support patients’ individual needs. To learn more, visit our website amicusblue-fresenius-kabi.com or contact us at tct.emea@fresenius-kabi.com.

4SC AG is a clinical-stage biopharmaceutical company focusing on the development of novel small molecule drugs that target key mechanisms of cancer development, such as histone deacetylases (HDAC). Such drugs are intended to provide patients with innovative treatment options that are more tolerable and efficacious than existing therapies and provide a better quality of life.

4SC’s current product pipeline includes one program in clinical development: resminostat.

4SC’s goal is to advance its own drug development programs in order to increase the value of the Company as a whole through entering into valuable partnerships with pharmaceutical and biotechnology companies for the further development or commercialization of 4SC’s drug candidates, and/or the eventual marketing and sales of approved drugs in select territories, such as Europe.

Almirall is a leading skin-health focused global pharmaceutical company based in Barcelona that partners with healthcare professionals, applying Science to provide medical solutions to patients and future generations. Our efforts are focused on fighting skin health diseases and helping people feel their best. We support healthcare professionals in continuous improvement, bringing our innovative solutions to where they are needed most. www.almirall.com

At la Roche-Posay we are committed to caring for the skin of cancer patients, limiting or delaying the side effects they may experience, and improving their well-being on a daily basis, before, during and after treatments. We work together with dermatologists and oncologists to fulfill our daily commitment to listen to the needs of cancer patients, to continue researching and developing, and to share our knowledge with healthcare professionals.

Sandoz is a global leader in biosimilars and is committed to playing a key role in achieving global healthcare goals by discovering new ways to improve and extend people’s lives and by pioneering new approaches to help people around the world access high-quality medicine. Our purpose is to increase physician and patient access to broader options for quality cancer treatments by providing sustainable innovation in cancer care. www.sandoz.com